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Abstract
Background: Antidotes stocking is a critical component of hospital care for poisoned patients in emergency.
Antidote stocking represents a major health challenge worldwide and in Lebanon. Systematic data monitoring of
antidote stocking in Lebanese hospitals is lacking. The objective of this study is to assess the adequacy of antidotes
stocking in Lebanese hospitals according to type and quantity and explore the characteristics associated with their
differential availability.
Methods: Data collection to assess antidote availability and its correlate was undertaken through a self-administered
questionnaire. The questionnaires were distributed by the unit of surveillance at the Ministry of Public Health to eligible
hospitals providing emergency care services. The list of essential antidotes was adapted from the World Health
Organization (WHO) list and the British Columbia Drug and Poison Information Centre.
Results: Among the 85 Lebanese hospitals surveyed none had in stock all the 35 essential antidotes required. The
frequency of stocking by type of antidote varied from a minimum of 1.2 % of the hospitals having a (cyanide kit) to
100 % availability of (atropine and calcium gluconate). Teaching hospitals and those with a large bed-capacity reported
a higher number of available antidotes for both immediate and non-immediate use than non-teaching hospitals while
controlling for the hospital geographical region and public vs private sector.
Conclusion: The Lebanese hospitals have a suboptimal stock of essential antidotes supply. It is recommended that the
Lebanese Ministry of Public Health monitors closely on the hospital premises the adequacy and availability of essential
antidotes stock.
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Background
An antidote, as defined by the World Health Organization
(WHO), is a therapeutic substance used to counteract the
toxic action(s) of a specified xenobiotic [1]. Although
emergency supportive care is considered the foundation of
toxicological emergency management, unintentional and
intentional poisoning continue to be a major contributor
to annual mortality rates worldwide [2]. Morbidity, mortal-
ity, and the length of hospitalization may be reduced by
the appropriate and well-timed use of antidotes [3]. The
mainstay in the proper management of a patient in need
for an antidote is the immediate administration of the
needed antidote and its availability in the hospital emer-
gency. Therefore hospitals and emergency centers should
be self-sufficient with regards to antidote stocking. Thus
improper stocking or unavailability of the required anti-
dotes are a major factors that lead to mismanagement of
poisoned patients.
Data on the availability of antidotes globally is scarce,
however recent studies have shown that antidotes are
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inadequately stocked in many countries and their
availability also varies significantly among hospitals
within the same country [3–6]. Accordingly, Dart et al.,
developed recommendations for antidote stocking and
categorizing their availability according to the immedi-
acy of their use in USA [7]. However, these recommen-
dations can be only elaborated when information on
antidotes stocking in hospitals providing Emergency care
is available. Considering such guidelines are still largely
missing in Lebanon, it is therefore recommended to first
document antidotes stocking before developing the
guidelines [7]. Data also shows that antidote stoking
varies by the hospital sector (public or private), bed
capacity, presence of particular medical specialists (e.g.,
emergency care), and number of expected poisoning
cases [3, 4]. Lebanon, a country of 4 million inhabitants
in the Middle East, has a healthcare system dominated
by the private sector, where less than 17 % of its hospi-
tals are administered by the public sector [8]. Lebanese
hospitals are usually well equipped with state-of-the art
medical equipment in the emergency department,
however, antidote availability and stocking are not well
monitored. The ministry of health reported an increase
in number of hospitalized cases due to poisoning by
drugs or toxic substances from 288 cases in 2011 to 336
cases in 2012 [8, 9]. A systematic evaluation of the
availability of antidote stocking in Lebanese hospitals has
not been undertaken to date. The main objective of this
study was to document the availability of antidotes consid-
ered essential according to the criteria set by the British
Columbia Drug and Poison Information Centre (BC
DPIC) and the World Health Organization (WHO) [1].
Methods
Study design
This is a cross sectional survey study that was undertaken
among eligible Lebanese hospitals that have an emergency
care setting. The data collection period extended from
October 2013 to April 2014 by contacting either the
emergency unit or pharmacy department in charge of
monitoring and providing antidotes in the hospitals. The
Lebanese Ministry of Public Health provided us with a list
of addresses and contact information of eligible public
and private hospitals with emergency care services in
Lebanon. The data collection instrument was a self-
administered survey that was distributed by the Lebanese
Ministry of Public Health, along with a document explain-
ing the objectives and significance of the study. The ques-
tionnaire was filed by the person responsible of stocking
the antidotes in the emergency unit or hospital pharmacy.
The questionnaire included questions on hospitals geo-
graphical distribution, working in the public or private
sector and type [university (teaching) vs general (non-
teaching)] (Additional file 1: Table S4). Also, the hospitals
were stratified according to their bed capacity into small
(<50 beds), medium (50–150 beds) and large (>150 beds).
Data on the availability of each antidote from a list of
35 antidotes was also collected as well as the reasons
when the antidote was not available (adapted from the
British Colombia Drug and Poison Information Centre
(BCDPIC) and the World Health Organization) [1]. The
latter guidelines were used since there are no current
specific guidelines for antidotes stocking in Lebanon.
The list of antidotes were also grouped into “immediate”
and “non-immediate” as per WHO guidelines. The group
of “immediate” are antidotes given within 30 min to one
hour and include: Activated Charcoal; Atropine; Calcium
Chloride; Calcium Gluconate; D50W; Digoxin F; Ethanol;
Flumanezil; Fomepizole; Glucagon; Glucose; Hydroxyco-
balamin; Methylene Blue; N-acetylcysteine; Naloxone;
Pyridoxine; Na bicarbonate; Na nitrate; Na thiosulfate.
The group of “non-immediate” antidotes that can be
administered after one hour of poisoning are: Cholestyr-
amine; Deferoxamine; Dimercaprol; EDTA; Folic Acid;
Insulin; Isoproterenol; Leucovorin; Magnesium; Octreotide;
PEG solution; Pralidoximine; Protamine sulfate; Prostigi-
mine; Vitamin K.
Surveys were distributed by the ministry of Public
Health surveillance unit to all eligible hospitals in the
first week of October 2013. After two months from the
initiation of the study a second reminder was sent and
those who did not reply were contacted by telephone. By
the end of April 2014 all hospitals that did not reply
were labeled as non-respondents.
Statistical analysis
Data analysis was done using Statistical Package for
Social Sciences (SPSS version 23) software for analysis.
The distribution of antidotes by categorical data such as
type of hospital was performed by using the chi-square
test. The independent sample t–test was used to com-
pare the mean antidotes in the different hospital types,
sectors, and location. Additionally, separate multiple
regression analysis were also performed in order to
explore the hospital characteristics as predictors related
to two outcomes number of immediate and non-
immediate antidote. Results were considered significant
with a p value of less than 0.05.
Results
Table 1 shows the characteristics of the 85 sampled
hospitals regarding bed capacity, type, and health sector.
More than half of the hospitals had a medium (50–150)
bed capacity (57.1 %), and the majority were non-
teaching (77.4 %) and privately owned (83.3 %) hospitals.
Table 2 describes the availability of antidotes according
to antidote type, it ranges from 1.2 % having cyanide kit
to 100 % having atropine and calcium gluconate. The
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number of reported antidotes available in each hospital
varies from 5–28 with no hospital having the total 35
antidotes in stock (data not shown).
Table 3 shows the reasons reported for not having
specific antidotes in stock in the hospitals. The major
reason was the availability of the antidote in a nearby
hospital followed by alternative medications being used
instead. Other reported reasons were: unavailable in the
Lebanese market, expensive or available in another
location within the hospital.
Distribution of antidotes by hospital geographical location
The hospitals located in Beirut and its suburbs have a
slightly higher number of antidotes in stock with a mean
of 19.05 ± 5.27 compared to 18.15 ± 4.04 in the other
governorates (p = 0.39). The mean number of antidote
availability for immediate and non-immediate by
geographic location was also not significant (Table 4). Of
note, there were significant differences between the
region of the hospital and only 5 different antidotes
(Additional file 2: Table S1).
Distribution of antidote by type of hospital
Private vs public
The distribution of the antidotes by hospital health
sector shows that the mean availability of antidote was
18.84 ± 4.85 in private hospitals versus 17.07 ± 2.79 in
public hospitals (p = 0.07), but a significant difference
was found between the availability of seven antidotes
(Digoxin immune F, Fomepizole, Glucagon, Octeotride,
Leucovorin, Isoproterenol, Pyridoxine) and the hospital
sector. Furthermore, atropine, calcium gluconate and
flumazenil were equally available regardless the hospital
sector (Additional file 3: Table S2). The mean number of
immediate antidotes available by type of hospital (Private
vs Public) did not differ significantly (p-value = 0.315).
However, the mean number of 7.7 for non-immediate
antidote availability in Private hospitals compared to 6.5
among Public hospitals was significantly different with a
p-value = 0.04 (Table 4).
Teaching vs non-Teaching
Additionally, our data showed that teaching hospitals
stocked an average of 22.21 ± 3.26 antidotes compared
to 17.48 ± 4.41 in non-teaching hospitals (p < 0.0001)
Table 1 Characteristics of the hospitals in Lebanon that were
evaluated during the study
Characteristic Percentage
Bed capacity
• Small (<50 beds) 23.8
• Medium (50–150 beds) 57.1
• Large (> 150 beds) 16.7
Type of hospital
• Teaching 77.4
• Non-teaching 22.6
Sector
• Public 16.7
• Private 83.3
Table 2 Prevalence of antidote stocking in Lebanese hospitals
Antidotes Hospitals
Percent
Atropine 100
Calcium gluconate 100
Glucose 98.8
Insulin 96.4
Sodium bicarbonate 96.4
Magnesium 95.2
Vitamin K 95.2
Naloxone 94.0
Flumazenil 85.7
Protamine sulfate 85.7
NAC 84.5
Prostigmine 83.3
Methylene blue 79.8
Activated charcoal 76.2
Folic acid 67.9
Pralidoxime 63.1
D50W 54.8
Glucagon 52.4
Hydroxycobalamin 44.0
Calcium chloride 44.0
Ethanol 40.5
Octeotride 32.1
PEG solution 41.7
Leucovorin 31.0
Deferoxamine 22.6
Digoxin immune F 21.4
Isoproterenol 20.2
Pyridoxine 19.0
Cholestyramine 6.0
EDTA 6.0
Sodium nitrate 6.0
Fomepizole 3.6
Sodium thiosulfate 3.6
Dimercaprol 2.4
Cyanide Kit 1.2
PEG polyethylene glycol electrolyte, D50W dextrose 50 % in water, NAC
N-acetylcysteine, EDTA Ethylenediaminetetraacetic acid
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and there was a significant difference between the
hospital type and nine different antidotes (Additional file 4:
Table S3). The mean number of immediate and non-
immediate antidote by type of hospital also differed signifi-
cantly. The mean number in non-teaching hospital for
immediate was 10.6 compared to 12.5 among Teaching
hospitals. For non-immediate Non-Teaching 6.8 and
Teaching 9.7 (Table 4).
Bed capacity
According to the bed capacity the mean availability was
16.90 ± 4.64, 18.48 ± 4.59, and 21.50 ± 3.46 for small,
medium and large hospitals respectively (p = 0.014), and
a significant difference was found between the hospital
size and the availability of seven different antidotes (octeo-
tride, leucovorin, glucagon, pralidoxime, protamine sul-
fate, naloxone, flumazenil). Moreover, glucose, insulin,
atropine, calcium gluconate and sodium bicarbonate were
equally available in small and large hospitals (Fig. 1).
Multiple regression analysis showed that the main pre-
dictor of the number of antidote availability is being a
teaching compared to non-teaching hospitals (P-value =
0.01) while controlling for hospital sector, geographical
area and bed capacity. Multiple regression analysis were
also done for immediate and non-immediate antidote
separately. Finally, multiple regression analysis showed a
similar result as observed for the total number of
antidotes where teaching hospitals again seem to have
the higher probability of having available both immedi-
ate and non-immediate significantly more than non-
teaching hospitals (Tables 5, 6 and 7).
Discussion
The main objective of this study was to evaluate the
adequacy of antidote stocking in Lebanese hospitals
providing emergency care services. Our results showed
that most hospitals had an insufficient number of the
main required antidotes which is consistent with other
studies from multiple countries [4, 10–12]. Hospitals
with a larger bed capacity had stocked more antidotes
when compared to smaller hospitals and these results
were similar to data found by others [6, 10, 12–14].
Moreover, we found that the mean number of antidotes
that are used either both immediately or non-immediately
is significantly different between types of hospitals with
teaching hospitals stocked higher number in each cat-
egory. Such finding is extremely important knowing that
most of the teaching hospitals are located in the capital
area while hospitals located away from the hospital might
lack lifesaving antidotes. The negative impact of lacking
important antidotes in areas far from the capital can be
minimize since the geographic area of Lebanon is small
enough rendering the communication between hospitals
an achievable task. In conclusion, antidote stoking of the
immediate category needs to be reevaluated particularly in
hospitals located outside the capital in order to prevent
and reduce the cost of care associated with the lack of
such antidotes. Regarding poisoning cases requiring the
use of non-immediate antidotes, the health impact of
Table 3 Reasons reported for Not Stocking Antidotes in
Lebanese hospitals
Antidote Percentage
Available in a nearby hospital (N=13)
Magnesium 100
Sodium bicarbonate 100
Vitamin K 100
Naloxone 75.0
Protamine sulfate 50.0
NAC 42.8
Fomepizole 37.5
Folic acid 35.7
Glucagon 35.5
Pralidoxime 35.0
Leucovorin 33.3
Hydroxycobalamin 29.2
Ethanol 32.1
Alternative can be used (N=8)
Activated charcoal 61.5
Calcium chloride 54.2
D50W 52.3
Dimercaprol 44.0
EDTA 40.4
Prostigmine 33.3
PEG solution 30.4
Isoproterenol 30.0
Not available in the market (N=6)
Cholestyramine 42.3
Cyanide Kit 36.2
Digoxin immune F 43.2
Pyridoxine 39.5
Sodium nitrate 43.8
Sodium thiosulfate 39.2
Expensive (N=3)
Flumazenil 40.0
Deferoxamine 29.2
Octeotride 25.7
Available in another place within hospital (N=2)
Insulin 66.6
Methylene blue 37.5
PEG polyethylene glycol electrolyte, D50W dextrose 50 % in water, NAC
N-acetylcysteine, EDTA Ethylenediaminetetraacetic acid
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lacking of such antidotes in a particular hospital can be
minimized since major hospitals can be reached at reason-
able time before irreversible organ damage occurs since
the geographic area of Lebanon is relatively small.
Several reasons for not stocking antidotes in smaller
hospitals were reported in a recent study in Australia
such as budget constraints, perceived lack of antidote
need, short expiry dates or the rapid transfer of patients
or antidotes [6]. Moreover, inadequate stocking of anti-
dotes in hospitals has also been attributed to the short
shelf-life, cost, and lack of awareness about the risks of in-
toxication. Additionally, hospitals may waive the stocking
of antidotes that can be quickly obtained from neighbor-
ing institutions in case of an emergency. Finally, one of
the key element in the inadequacy of antidotes stocking in
the hospital pharmacy is the absence of stocking and man-
agement guidelines as well as their implementation [11].
Worthy to note that the number of antidotes among
hospitals did significantly differ according to the geo-
graphic area emphasizing the role of the LMPH to
provide hospitals in far areas with enough medical
resources. However, better policies of antidotes stock-
ings are needed to further uncover the needs for
particular antidotes in these hospitals. For instance,
atropine is available in all hospitals located nearby
agriculture areas (usually far from the capital) where
the risk of exposure to pesticide poisoning (organo-
phosphates and carbamate poisoning) is high. Of
note, pesticide poisoning is becoming a major prob-
lem globally and causing thousands of death, it neces-
sitate immediate infusion of the antidote “atropine”
along with ventilation support [15, 16]. Hence, the
availability of atropine in these hospitals is critical
and its availability can limit the catastrophic out-
comes associated with delaying treatment.
Cyanide poisoning requires immediate and aggressive
treatment and its clinical diagnosis is usually difficult as
no specific symptoms are present, whereas laboratory
findings require hours to confirm a diagnosis [17].
Therefore, an antidote should be administered when
cyanide poisoning is suspected. In Lebanon, the cyan-
ide kit is the least available antidote which raises con-
cern when a case of cyanide poisoning is suspected.
Other alternatives approved for empirical therapy in
cyanide poisoning include sodium thiosulfate and
hydroxycobalamin [18], but they are available in less
than 50 % of all hospitals, hence cases of cyanide poi-
soning cannot be adequately treated. Even though in
such incidences the antidotes can be requested from
nearby hospitals, the issue of delivery time remains
the main concern in Lebanon due to traffic jams or
distances between hospitals.
On the other hand, no association has been documented
between the hospital sector and the mean availability of
antidotes. Subsequently, fomepizole and digoxin immune
F, two expensive antidotes used in the treatment of alcohol
and digoxin toxicity respectively, were significantly present
in public rather than private hospitals highlighting the fact
that the public sector funded by the ministry of health had
better capabilities of obtaining more expensive antidotes.
The number of public hospitals in Lebanon account for
17 % of the total hospitals [8] and the difference of anti-
dote stocking can be attributed to the different poisoning
cases encountered and the budget drafted by each of the
hospitals sectors. Although, Greater Beirut area has a
greater population and more poisoning cases would be
Table 4 Analysis of immediate and non-immediate antidotes availability according to hospital type, geographic area and hospital sector
N Mean Std. deviation Std. error mean P-value
Mean number of immediate and non-immediate antidotes availability according to hospital type
Immediate Non-teaching 65 10.6308 2.69588 0.33438 0.001
Teaching 19 12.4737 1.71167 0.39268
Non-immediate Non-teaching 65 6.8308 2.13285 0.26455 0
Teaching 19 9.7368 1.75885 0.40351
Analysis of antidote availability according to geographic area (region)
Immediate Greater Beirut 37 11.1622 2.88207 0.47381 0.315
Others 47 10.9574 2.41335 0.35202
Non-immediate Greater Beirut 37 7.8919 2.70579 0.44483 0.04
Others 47 7.1702 2.06755 0.30158
Mean number of antidote availability according to hospital sector
Immediate Private 70 11.1571 2.71141 0.32408 0.394
Public 14 10.5 2.06621 0.55222
Non-immediate Private 70 7.6714 2.48311 0.29679 0.04
Public 14 6.5714 1.55486 0.41555
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Fig. 1 Represents the distribution of the different antidotes among small (24.40 %), medium (58.50 %) and large (17.10 %) hospitals. *p < 0.05
significance different between hospital sizes and each specific antidote
Table 5 Regression analysis of the mean antidote availability according to hospital type (teaching vs non-teaching), geographical
region and bed capacity
Coefficientsa
Model Unstandardized coefficients Standardized coefficients t Sig.
B Std. error Beta
1 (Constant) 11.239 3.059 3.674 .000
Hospital type 4.674 1.315 .429 3.554 .001
Sector -1.780 1.389 -.137 -1.281 .204
Region 1.294 1.038 .140 1.247 .216
Bed capacity .856 .848 .119 1.010 .316
aDependent Variable: Mean antidotes
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expected and managed in this area as compared to
the other governorates, an equal distribution of the
number of antidotes was documented among all
regions in Lebanon and thus there was no
centralization among the distribution of antidotes in
the capital area and its suburbs. On the other hand,
the fact that university hospitals acquired a larger
number of antidotes when compared to non-teaching
hospitals can be attributed to the higher funding of
university hospitals and the variety of clinical expo-
sures needed to be provided to medical students.
Although, this study was relied on antidote lists devel-
oped both locally and externally, which may not accurately
reflect the coverage required for toxicological emergencies
in Lebanon, it may represent an important step toward
implementing better antidote stocking policies. Since hos-
pitals didn’t often report the quantity of each antidote they
possess so we were unable to determine whether an anti-
dote was stocked in sufficient amount.
Conclusions
This study showed an inadequate antidote stocking in
the Lebanese hospitals and that the mean number of
antidote available was significantly greater in teaching
hospitals vs non-teaching hospitals. Establishing a national
antidote database to enhance communication between
health institutions regarding their stocks of antidote will
lead to a better and effective antidote stocking system.
The Lebanese Ministry of Public Health should also re-
view and implement new guidelines regarding stocking of
antidotes, taking into consideration the WHO recommen-
dations and the type of toxicological cases in Lebanon.
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